Browse > Article

The Palliative Effect of Endobronchial Brachytherapy for Previously Irradiated Patients with Lung Cancer  

Park, Young-Je (Departments of Radiation Oncology, College of Medicine, Korea University)
Kim, Kwang-Taik (Departments of Thoracic Surgery, College of Medicine, Korea University)
Yang, Dae-Sik (Departments of Radiation Oncology, College of Medicine, Korea University)
Lee, Suk (Departments of Radiation Oncology, College of Medicine, Korea University)
Kim, Chul-Yang (Departments of Radiation Oncology, College of Medicine, Korea University)
Publication Information
Radiation Oncology Journal / v.25, no.3, 2007 , pp. 177-184 More about this Journal
Abstract
Purpose: To evaluate the palliative effect of endobronchial brachytherapy (EBB) for patients with lung cancer that previously received external beam radiotherapy (EBRT). Materials and Methods: From July 1992 to May 2003, 29 patients with a recurrent or persistent lung cancer were treated with palliative EBB at our institute. EBB consisted of three fractions (once a week) of a dose of 5 Gy using the high dose-rate remote afterloader. Symptomatic improvement was assessed subjectively, and patients were divided into two groups according to whether symptoms were improved or not. Factors such as age, performance status, duration from EBRT to EBB and the location of the tumor were compared between the improved and unimproved groups of patients. Results: Overall symptomatic improvement was found in 27 out of 52 symptoms (52%). Improvement as to the type of symptoms was seen in 41 %, 50%, 82% and 33% of patients with cough, dyspnea, hemoptysis, and obstructive pneumonia respectively. The rate of improvement of hemoptysis was more than that of cough (p<0.05). The median time to symptom relapse was 5 months. The improved patient group (n=17, 59%) had a better performance status and longer duration from EBRT to EBB than the unimproved patient group (p<0.05). Lesions located in the distal trachea and/or main bronchus were found more frequently in the improved group of patients than in the unimproved group of patients, but the difference was not statistically significant (p=0.06). Fatal complications developed in two patients (7%), which were a hemoptysis and bronchopleural fistula respectively. Conclusion: Symptom improvement was found in 60% of patients after EBB and improvement was maintained for 5 months. Palliative EBB, even when EBRT was given previously, can be effective for a patient that has an endobronchial symptom, such as hemoptysis, and for a patient with good performance and a long duration from previous EBRT to EBB.
Keywords
Lung cancer; Endobronchial brachytherapy; Palliative treatment;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Freitag L, Ernst A, Thomas M, Prenzel R, Wahlers B, Macha HN. Sequential photodynamic therapy (PDT) and high dose brachytherapy for endobronchial tumour control in patients with limited bronchogenic carcinoma. Thorax 2004;59:790-793   DOI   ScienceOn
2 Huber RM, Fischer R, Hautmann H, Pollinger B, Haussinger K, Wendt T. Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors. Int J Radiat Oncol Biol Phys 1997; 38:533-540   DOI   ScienceOn
3 Taulelle M, Chauvet B, Vincent P, et al. High dose rate endobronchial brachytherapy: results and complications in 189 patients. Eur Resp J 1998;11:162-168   DOI
4 Gollins SW, Ryder WDJ, Burt PA, Barber PV, Stout R. Massive hemoptysis death and other morbidity associated with high dose rate intraluminal radiotherapy for carcinoma of the bronchus. Radiother Oncol 1996;39:105-116   DOI   ScienceOn
5 Kelly JF, Delclos ME, Morice RC, Huaringa A, Allen PK, Komaki R. High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: The 10-year M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 2000;48:697-702   DOI   ScienceOn
6 Gollins SW, Burt PA, Barber PV, Stout R. High dose rate intraluminal radiotherapy for carcinoma of the bronchus: outcome of treatment of 406 patients. Radiother Oncol 1994;33: 31-40   DOI   ScienceOn
7 Hennequin C, Bleichner O, Tredaniel J, et al. Long-term results of endobronchial brachytherapy: a curative treatment? Int J Radiat Oncol Biol Phys 2007;67:425-430
8 Ofiara L, Roman T, Schwartzman K, Levy RD. Local determinants of response to endobronchial high-dose rate brachytherapy in bronchogenic carcinoma. Chest 1997;112:946-953   DOI   ScienceOn
9 Boxem T, Muller M, Venmans B, Postmus P, Sutedja T. Nd-YAG laser vs bronchoscopic electrocautery for palliation of symptomatic airway obstruction: A cost-effectiveness study. Chest 1999;116:1108-1112   DOI   ScienceOn
10 Langendijk H, Jong JD, Tjwa M, et al. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study. Radiother Oncol 2001;58:257-268   DOI   ScienceOn
11 Vergnon JM, Huber RM, Moghissi K. Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers. Eur Respir J 2006;28:200-218   DOI   ScienceOn
12 Sheski FD, Mathur PN. Cryotherapy, electrocautery, and brachytherapy. Clin Chest Med 1999;20:123-138   DOI
13 Stout R, Barber P, Burt P, et al. Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs. external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer. Radiother Oncol 2000;56:323-327   DOI   ScienceOn
14 Wu KL, Jiang GL, Qian H, et al. Three-dimensional conformal radiotherapy for locoregionally recurrent lung carcinoma after external beam irradiation: a prospective phase I-II clinical trial. Int J Radiat Oncol Biol Phys 2003;57:1345-1350   DOI   ScienceOn
15 Ahn YC, Lim DH, Choi DR, et al. Short-term results of endobronchial brachytherapy for malignant airway obstructions. J Korean Soc Ther Radiol Oncol 1996;14:299-306
16 Langendijk JA, Tjwa M, Jong JD, Velde GT, Wouters E. Massive hemoptysis after radiotherapy in inoperable non-small cell lung carcinoma: is endobronchial brachytherapy really a risk factor? Radiother Oncol 1998;49:175-183   DOI   ScienceOn
17 Hara R, Itami J, Aruga T, et al. Risk factors for massive hemoptysis after endobronchial brachytherapy in patients with tracheobronchial malignancies. Cancer 2001;92:2623-2627   DOI   ScienceOn
18 Ung YC, Yu E, Falkson C, Haynes AE, Stys-Norman D, Evans WK. The role of high-dose-rate brachytherapy in the palliation of symptoms in patients with non-small-cell lung cancer: A systemic review. Brachytherapy 2006;5:189-202   DOI   ScienceOn
19 The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown & Co. 1994:253-256
20 Cavaliere S, Venuta F, Foccoli P, Toninelli C, La Face B. Endoscopic treatment of malignant airway obstructions in 2,008 patients. Chest 1996;110:1536-1542   DOI   ScienceOn
21 Tada T, Fukuda H, Matsui K, et al. Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy. Int J Clin Oncol 2005;10:247-250   DOI